In 2026, Co-Diagnostics entered an agreement with ReadyGo to assess whether its sample collection and preparation technologies are compatible with the Co-Dx PCR platform. The evaluation may streamline decentralized molecular testing, but remains preliminary and creates no obligation for development, supply, commercialization or another commercial arrangement.

Key Highlights

  • ReadyGo has agreed to provide sampling materials for feasibility and compatibility studies involving Co-Diagnostics’ products.
  • The technologies are designed to collect samples, stabilize nucleic acids and prepare biological material for molecular analysis.
  • Co-Diagnostics’ Co-Dx PCR platform and associated tests remain subject to regulatory review and are not available for sale.

In August 2026, Co-Diagnostics, Inc. (NASDAQ: CODX) entered into an agreement with ReadyGo Diagnostics Ltd. to evaluate whether ReadyGo’s sample collection and preparation technologies are compatible with its Co-Dx PCR platform.

ReadyGo Materials Enter Feasibility Testing

Under the agreement, ReadyGo will provide certain sampling materials for feasibility studies and compatibility testing with Co-Diagnostics’ products. Co-Diagnostics believes those technologies may be complementary to its Co-Dx PCR platform, which is being developed around a compact instrument and proprietary test cups for real-time PCR testing outside traditional laboratory settings. The work reflects Co-Diagnostics’ stated objective of expanding access to molecular diagnostics in decentralized and point-of-care settings. Dwight Egan, chief executive officer, signed on behalf of Co-Diagnostics on Sep. 15, 2026.